EGF結合パクリタキセル封入ナノ粒子による抗腫瘍効果の増強

EGF结合紫杉醇封装纳米粒子增强抗肿瘤作用

• 批准号: 16790760
• 负责人: 嶋田 俊之
• 金额: $ 1.86万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2004
• 资助国家: 日本
• 起止时间: 2004 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16790760/
• 关键词: EGF; MPCポリマー; paclitaxel; ターゲッティング療法; Paclitaxel

乳癌細胞株(BT-20)、扁平上皮癌細胞株(A431)、肺小細胞癌株(H69)に対するEGF結合paclitaxel (PTX)封入MPCポリマーの殺細胞効果をMTT assayを用いてEGF非結合のMPCポリマーと比較検討した。EGFR過剰発現扁平上皮癌細胞株であるA431に対するinhibition rateは、EGF結合PTX封入MPCポリマー群で84.1%、EGF非結合PTX封入MPCポリマー群で30.2%であり、EGFを結合させた群で有意に殺細胞効果が高かった(p<0.05)。またEGFR過剰発現乳癌細胞株であるBT-20においても、EGF結合PTX封入MPCポリマー群と非結合群でのinhibition rateはそれぞれ51.1%、40.1%でEGF結合群において有意に高かった(p<0.05)。一方、EGFR低発現細胞株であるH69においては両群間で殺細胞効果に有意差は認めなかった。A431は、EGFの存在下で殺細胞効果を認めたため、EGF結合PTX封入MPCポリマーの殺細胞効果が、EGFとPTXによる相加効果にすぎないのか、相乗効果であるかの判定を二元配置分散分析法で行った結果、相乗効果であった。以上より、EGFR過剰発現株において、EGF結合PTX封入MPCポリマーによる殺細胞効果の増加を認めたことになる。動物実験においては、(1)PTX封入MPCポリマー(2)EGF結合PTX封入MPCポリマー、(3)生食、(4)従来のPTXの4つの群に分け、抗腫瘍効果の違いを検討した。PTX濃度は15mg/kg、投与経路は腹腔内投与で5日間連続投与とした。試薬投与後21日目における抗腫瘍効果は、EGF結合PTX封入MPCポリマー群がPTX封入MPCポリマー群に比して有意に高かった(p<0.05)が、生存期間には有意差を認めなかった。いずれの群においても体重減少などの副作用は認めなかった。

Breast cancer cell line (BT-20), flat epithelial carcinoma cell line (A431) and lung small cell carcinoma cell line (H69) were sealed with EGF and paclitaxel (PTX). The results showed that MTT assay was not combined with MPC cell EGF. The results of EGFR screening showed that the flat epithelial carcinoma cell line, strain A431, inhibition rate, EGF combined with PTX, EGF with PTX, and EGF with PTX, were 84.1%, 84.1%, 30.2% and 0.05 respectively. The results of EGFR screening showed that breast cancer cell lines were isolated from breast cancer cell lines, which were blocked by EGF and PTX into the unsociable group, the EGF group was 51.1% and 40.1%, respectively, and the EGF group was interested in high risk (pairlt). On the other hand, the EGFR low cell strain H69 cell line was found to have an intentional difference in the cell cycle between the two groups. In the presence of A431 and EGF, the results showed that the results were compared with the results of the binary configuration dispersion analysis method, the results of the binary configuration dispersion analysis method, the results of the binary configuration dispersion analysis method, the results of the binary configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method, the results of the binary configuration dispersion analysis method, the results of the two-dimensional configuration dispersion analysis method All of the above, EGFR, EGF and PTX were used to seal the cells of MPC cells. The animals were killed, (1) PTX was sealed in MPC, (2) EGF combined with PTX was sealed in MPC, (3) raw food, (4) PTX was used in 4 groups, and anti-virus was used. PTX dose 15mg/kg, intraperitoneal injection and "road" intraperitoneal injection and "5 days" intraperitoneal injection. In the following 21 days, the target anti-cancer results were reported, and the combination of EGF and PTX was used to seal the MPC immune group. The PTX was sealed into the MPC immune group, and the survival period was significantly higher than that of the control group (PSTX 0.05). I don't know. I don't have any weight. I don't know. I don't know.